NASDAQ:ORGS Orgenesis (ORGS) Stock Price, News & Analysis $0.80 +0.00 (+0.62%) (As of 10:36 AM ET) Add Compare Share Share Today's Range$0.79▼$0.8350-Day Range$0.45▼$1.0052-Week Range$0.25▼$1.08Volume17,880 shsAverage Volume186,080 shsMarket Capitalization$37.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrends Get Orgenesis alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Orgenesis Stock (NASDAQ:ORGS)Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Read More ORGS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORGS Stock News HeadlinesAugust 16, 2024 | investing.comOrgenesis forms joint venture with Harley Street HealthcareAugust 14, 2024 | globenewswire.comOrgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative GloballyAugust 22, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…August 13, 2024 | msn.comWhy Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving PremarketAugust 9, 2024 | msn.comORGS Stock Earnings: Orgenesis Reported Results for Q2 2024August 8, 2024 | markets.businessinsider.comOrgenesis Provides Second Quarter 2024 Business UpdateMay 31, 2024 | investorplace.comORGS Stock Earnings: Orgenesis Reported Results for Q4 2023May 21, 2024 | investorplace.comORGS Stock Earnings: Orgenesis Misses Revenue for Q1 2024August 22, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…May 21, 2024 | globenewswire.comOrgenesis Provides Business Update for the First Quarter of 2024April 17, 2024 | investing.comOrgenesis secures $2.3 million investment and strategic partnershipApril 17, 2024 | finanznachrichten.deOrgenesis Inc.: Orgenesis Provides Year End Business UpdateApril 15, 2024 | globenewswire.comOrgenesis Provides Year End Business UpdateApril 11, 2024 | investing.comGermfree partners with Orgenesis to enhance CGT productionApril 10, 2024 | globenewswire.comGermfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global AccessibilityMarch 18, 2024 | globenewswire.comVered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe ConferenceMarch 13, 2024 | globenewswire.comOrgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic ExosomesMarch 4, 2024 | globenewswire.comOrgenesis Inc. Announces $2.3 Million Private PlacementSee More Headlines Receive ORGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2023Today8/21/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORGS CUSIPN/A CIK1460602 Webwww.orgenesis.com Phone(480) 659-6404FaxN/AEmployees150Year Founded2008Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,360,000.00 Net Margins-6,857.25% Pretax Margin-4,447.89% Return on EquityN/A Return on Assets-190.67% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$530,000.00 Price / Sales69.97 Cash FlowN/A Price / Cash FlowN/A Book Value($0.34) per share Price / Book-2.32Miscellaneous Outstanding Shares46,930,000Free Float32,497,000Market Cap$37.08 million OptionableOptionable Beta1.23 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Vered Caplan M.Sc. (Age 55)Chairperson of the Board, CEO & President Comp: $341.38kProf. Sarah Ferber Ph.D. (Age 70)Founder & Chief Scientific Officer Comp: $268.32kMr. Victor Miller (Age 54)CFO, Secretary & Treasurer Pierre LammeretzInterim Chief Operating OfficerDr. Shimon Hassin Ph.D.Chief Technology OfficerMr. Evan FishmanChief Financial Officer of Orgenesis BiotechMr. Joseph CarpinelliChief Financial Officer of OctomeraMore ExecutivesKey CompetitorsEnlivex TherapeuticsNASDAQ:ENLVChembio DiagnosticsNASDAQ:CEMICompass TherapeuticsNASDAQ:CMPXMersana TherapeuticsNASDAQ:MRSNDiaMedica TherapeuticsNASDAQ:DMACView All CompetitorsInsidersJacob SafierBought 10,100 shares on 2/1/2024Total: $3,333.00 ($0.33/share)Jacob SafierBought 25,000 shares on 1/30/2024Total: $8,250.00 ($0.33/share)Jacob SafierBought 25,000 shares on 1/25/2024Total: $8,000.00 ($0.32/share)Jacob SafierBought 10,000 shares on 1/22/2024Total: $2,900.00 ($0.29/share)Jacob SafierBought 10,000 shares on 1/18/2024Total: $3,300.00 ($0.33/share)View All Insider Transactions ORGS Stock Analysis - Frequently Asked Questions How have ORGS shares performed this year? Orgenesis' stock was trading at $0.5007 on January 1st, 2024. Since then, ORGS shares have increased by 58.8% and is now trading at $0.7951. View the best growth stocks for 2024 here. How were Orgenesis' earnings last quarter? Orgenesis Inc. (NASDAQ:ORGS) announced its quarterly earnings data on Friday, August, 11th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by $0.21. The company had revenue of $6.98 million for the quarter. Does Orgenesis have any subsidiaries? The following companies are subsidiaries of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc. How do I buy shares of Orgenesis? Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ORGS) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
